Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

6.1%

45 terminated/withdrawn out of 737 trials

Success Rate

89.2%

+2.6% vs industry average

Late-Stage Pipeline

20%

145 trials in Phase 3/4

Results Transparency

11%

40 of 371 completed trials have results

Key Signals

74 recruiting40 with results34 terminated11 withdrawn

Enrollment Performance

Analytics

N/A

179(32.5%)

Phase 2

169(30.7%)

Phase 4

86(15.6%)

Phase 3

59(10.7%)

Phase 1

56(10.2%)

Early Phase 1

1(0.2%)

550Total

N/A(179)

Phase 2(169)

Phase 4(86)

Phase 3(59)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (737)

Showing 20 of 737 trials

NCT07556770Completed

Sonographic Safety Margins of Subclavian Vein: Effect of View and Arm Position

Role: lead

NCT05418556Phase 4Recruiting

OPTIMIZE-APT: Tailored Versus Conventional Antiplatelet Therapy After Intravascular Imaging-guided Drug-eluting Stent Implantation

Role: lead

NCT07824531Active Not Recruiting

Feasibility of Vision-Language Models for Detecting Physical Assistance as an Observable Criterion Defining GMFCS Levels in Children Aged 2 to 6 Years With Cerebral Palsy

Role: collaborator

NCT07821775Completed

Robotic vs Laparoscopic and Open Surgery for Abdominopelvic Cancers

Role: lead

NCT07530393Recruiting

Blood Viscosity and Outcomes After Elective Craniotomy

Role: lead

NCT07485855Phase 3Recruiting

Influenza Vaccination Strategy for Patients With Hematologic Malignancy

Role: lead

NCT07792772Not ApplicableCompleted

Arrhythmia Detection With MEMO Patch Plus in Patients With Acute Heart Failure

Role: collaborator

NCT05507749Not ApplicableActive Not Recruiting

Cyroablation for Pulmonary Vein Isolation Alone in Patients With Early Persistent AF Assessed by Continuous Monitoring

Role: collaborator

NCT04782375Phase 4Completed

Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B

Role: lead

NCT07735897Not Yet Recruiting

Long Term Cohort Study of Adding Ovarian Function Suppression to Tamoxifen in Young Women

Role: collaborator

NCT06099366Phase 2Recruiting

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Role: collaborator

NCT06257394Phase 2Recruiting

Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea

Role: collaborator

NCT06184009Phase 2Recruiting

Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

Role: collaborator

NCT07730840Phase 3Not Yet Recruiting

Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke

Role: lead

NCT07726901Not ApplicableRecruiting

Empirical Anatomy-Based Ablation vs Emphasize Map-Guided Substrate Ablation in Persistent Atrial Fibrillation : (COMPASS-AF)

Role: collaborator

NCT05148286Phase 4Recruiting

Albumin and Crystalloid Administration in Septic Shock

Role: lead

NCT06929897Not ApplicableEnrolling By Invitation

PVI Alone vs PVI With Posterior Wall Isolation for Pulse-Field Ablation in Persistent AF

Role: collaborator

NCT07010497Phase 2Recruiting

A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma

Role: lead

NCT07431762Phase 4Recruiting

Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprosthetic Heart Valve Replacement

Role: lead

NCT07670962Not Yet Recruiting

Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy

Role: lead